Bayley-Pinneau (BP), Roche (R) and Tanner (T) height predictions in various conditions. The 3 predictions a t chronological ages (CA) 9 to 16 years were compared with adult height in 57 children. In normal boys (n = 15), R and T were most accurate from 9 to 12 years CA (mean prediction error -2.0 to 1.9 cm) and BP overestimated a t 9 years (4.6 cm). In normal girls (n = 16), the 3 methods were
about equal (-2.8 t o-t al l stature (4 m, 4 f), R and T were better than BP. In precocious puberty (4 m, 3 f), BP was accurate (1.8 cm), but R and T grossly overestimated at 10 years CA (20.9 and 27.5 cm). In Turner's s ndrome (4 f), all overestimated at 9 years, R and T .
-. i ' c m ) than 8) (2.2 cm). The same was found in dwarfism (4 f) and
Russell-Silver syndrome (3 m). It is concluded that R and T
give better overall results, if bone age does not deviate more than obout f 2 years from CA. In conditions with larger differences, BP is more accurate. (D.c.A.) with l a c k of adrenarche : catch-up of growth with dehydroepiandrostorone s u l f a t e (DHAs) therapy. W e have good evidence that t h e r e a r e 2 main t y p e s of DGA : i n type I growth and bone age (BA) v e l o c i t i e s u s u a l l y slow down between 618 y e a r s ( y ) , sometimes e a r l i e r , i n c h i l d r e n who o f t e n have s h o r t s t a t u r e ; i n type I1 t h e decrease of growth and BA s t a r t s between 12/13 y i n g i r l s and 13/14 y i n boys. A l a c k of adrenarche a s i n d i c a t e d by low plasma l e v e l s of dehydroepisndrosterone (DHA) i s present i n typeI; normal adrenarche i s present i n type I1 a s i n hypogonadotrcphic hypogonadism. To t e s t the$pothesia that t h e l a c k of adrenarche i s r e s p o n s i b l e f o r t h e DCL i n type I we s t u d i e d t h e e f f e c t of DILLS therapy i n a 12 y o l d g i r l with t y p i c a l type I. Except f o r c o n s i s t e n t l y low plasma l e v e l s of DHA : 10 t o 22 ng/dl, a l l endocrine f u n c t i o n s were normal. DIWS was given as a s i n g l e o r a l morning dose of 5 mg/day f o r one y : growth v e l o c i t y increased from 3.5 t o 9 with a growth over FA v e l o c i t i e s r a t i o = 1.3. From t h i s p r e l i m i r nary study we suggest t h a t a l a c k of adrenarche i s respons i b l e f o r t h e delayed maturation i n DGA type I and that o r a l DILiS could be a u s e f u l s u b s t i t u t i v e therapy.
M. RANKE* and J.R. BIERICH.
1 5 Dept. of Diagnostic Endocrinology, University, Children's Hospital, --Tubiigen, Germany. Comparison of circulating human growth hormone measured by radioimmunoassay (RIA) and radioreceptorassay (RRA) in plasma of children.
The binding characteristics of cultured human lymphocytes-IM9 in a plasmafree sample have been already definied (1). A modification of the original RRA method with IM-9 cells allows measurements of hGH in plasma at concentrations above 3.5 ndml (sensitivity of the RIA approx. 0.5 ndml) using only 0.1 ml plasma. A parallel study of hGH by RRA and RIA was carried out in 41 GH-deficient but receiving 4 I.U. of GH and 41 constitutionally short stature children duuring sleep. The results gave good agreement between RRA and RIA values (14.79, p4.05) and showed a parallelism between the regression lines after GH administration (RRA4.38 5 0.807 RIA) and during sleep (RRA=0.49+0.808 RIA). Sigle observations indicate that circulating hGH sometimes shows marked heterogeneity in respect to immunological and biological activity. 
E. d e PERETTI, M.G. FOREST, L. DAVID, R. FRANCOIS

and J. BERTRAND, INSERM, U. 34, H z p i t a l Debrousse and H z p i t a l Edouard-Herriot, Lyon, France. Dehydroepiandrosterone (DHA), i t s s u l f a t e (DHAS), 17-hydroxyprogesterone (OW) and c o r t i s o l (F) l e v e l s i n panhypopit u i t a r i s m (group I ) and i s o l a t e d GH d e f i c i e n c y (group 11) :
Evidence f o r a p i t u i t a r y hormone c o n t r o l l i n g adrenal androgens biosynthesis.
Ten s u b j e c t s of groupI(10-22 years) were studied i n comparison of 11 s u b j e c t s of group I1 (8-15 y e a r s ) . I n group I1 normal ACTH production was documented on ACTH l e v e l s and normal responses t o Metyrapone. As expected, adrenal androgens (DM, DHAS) a s w e l l a s OHP and F were extremely low i n group I, r e f l e c t i n g the secondary adrenal i n s u f f i c i e n c y . I n c o n t r a s t group I1 had normal F and OHP b a s a l l e v e l s f o r pub e r t a l s t a g e but on the c r i t e r i a of adrenal androgens l ev e l s , 3 subgroups were found : DHA, DHAS were e i t h e r normal f o r age (A : 2 g i r l s 12-14 y r s ) o r low f o r age but consist e n t with delayed adrenarche (B : 3 boys 15-19 y r s ) o r drast i c a l l y low whatever age o r p u b e r t a l s t a g e (C : 3 g i r l s 8-16 y r s ; 3 boys 8-13 y r s ) . Thus i n 112 of group I1 with appar e n t l y only GH d e f i c i e n c y but normal ACTH l e v e l s , impaired adrenal androgen production was documented. This suggests t h a t a p i t u i t a r y t r o p h i c hormone, lacking i n s u b j e c t s of subgroup I I -C , c o n t r o l s t h e adrenal androgen production. Impairment of t h y r o i d f u n c t f o n h a s been r e p o r t e d i n growth hormone d e f i c i e n t c h i l d r e n being t r e a t e d w i t h human growth hormone, and t h e r e i s evidence t h a t t h i s i s t h e r e s u l t of i n h i b i t i o n of t h e TSH response t o TRH. W e have t h e r e f o r e c a r r i e d o u t a number of t e s t s of t h y r o i d f u n c t i o n in 1 0 c h i l d r e n on human growth hormone treatment.
Basal TSH l e v e l s and the TSH l e v e l s 20 minutes a f t e r an i n j e c t i o n of TRH were normal i n e v e r y case. In o n l y one p a t i e n t was t h e serum thyroxine l e v e l low and in this p a t i e n t the growth response t o human growth hormone was v e r y good. It i s concluded t h a t t h e regime of treatment with human growth hormone recommended by t h e Medical Research Council does n o t s i g n i f i c a n t l y a f f e c t t h y r o i d function.
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